Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeconomic Impact

Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeconomic Impact

Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeconomic Impact

Treating iron deficiency in your patients with heart failure can change the course of heart disease and improve lives. Tune in to find out more.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.

    In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mikhail N. Kosiborod, MD
    Professor of Medicine
    Saint Luke's Hospital of Kansas City
    Kansas City, MO 

    Research Grant: AstraZeneca, Boehringer Ingelheim
    Consulting Fees: Amarin, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Glytec, Janssen, Merck (Diabetes), Novartis, Novo Nordisk, Sanofi, Vifor Pharma
    Other Research Support: AstraZeneca
    Honorarium: AstraZeneca, Boehringer Ingelheim, Novo Nordisk

    Ewa A. Jankowska, MD, PhD, FESC
    Professor and Head of Laboratory of Applied Research on Cardiovascular System
    Department of Heart Diseases
    Wroclaw Medical University
    Wroclaw, Poland

    Consulting Fees: Vifor Pharma
    Commercial Interest Speakers Bureau: Vifor Pharma

    Professor Phil McEwan, PhD
    Chief Executive Officer
    Health Economics & Outcomes Research Ltd
    Cardiff, United Kingdom 

    No relationship reported

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • James Seternus, DO, has nothing to disclose
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the impact of iron deficiency on outcomes of hospitalized patients with HFrEF
    • Explain the therapeutic and pharmacoeconomic role of iron replacement on HRQoL in patients with HFrEF and iron deficiency
    • Discuss the implications of iron replacement therapy on rehospitalization rates
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free